Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: A case report and a review of the literature

Acta Dermato-Venereologica

Volumn 90, Issue 1, 2010, Pages 73-76

  Kuraishi, Natsuki ^a   Nagai, Yayoi ^a   Hasegawa, Michiko ^a   Ishikawa, Osamu ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Imatinib mesylate; Lichenoid drug eruption; Palmoplantar hyperkeratosis

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; IMATINIB;

ACANTHOSIS; ADULT; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HISTOLOGY; HUMAN; HUMAN TISSUE; LICHEN PLANUS; LICHENOID ERUPTION; MALE; PALMOPLANTAR KERATODERMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; SKIN BIOPSY; SKIN PRURITUS;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; FEMALE; HUMANS; KERATODERMA, PALMOPLANTAR; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LICHENOID ERUPTIONS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; RECURRENCE; SKIN; TREATMENT OUTCOME;

EID: 76349087608     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0758     Document Type: Article

References (17)

1. Lim D, Muir J. Oral lichenoid reaction to imatinib (STI 571, Gleevec). Dermatology 2002; 205: 169-171.
2. Roux C, Boisseau-Garsaud AM, Saint-Cyr I, Helenon R, Quist D, Delaunay C. Lichenoid cutaneous reaction to imatinib. Ann Dermatol Venereol 2004; 131: 571-573.
3. Ena P, Chiarolini F, Siddi GM, Cossu A. Oral lichenoid eruption secondary to imatinib (Glivec). J Dermatol Treat 2004; 15: 253-255.
4. Prabhash K, Dovel DC. Lichenoid eruption due to imatinib. Indian J Dermatol Venereol Leprol 2005; 71: 287-288.
5. Pascual JC, Matarredona J, Miralles J, Conesa V, Borras-Blasco J. Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases. Int J Dermatol 2006; 45: 1471-1473.
6. Dalmau J, Peramiquel L, Puig L, Fernandez-Figueras MT, Roe E, Alomar A. Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect. Br J Dermatol 2006; 154: 1199-1219.
7. Basso FG, Boer CC, Correa ME, Torrezan M, Cintra ML, de Magalhaes MH, et al. Skin and oral lesions associated to imatinib mesylate therapy. Support Care Cancer 2009; 17: 45-48.
8. Chan CYS, Browning J, Smith-Zagone MJ, Martinelli PT, Hsu S. Cutaneous lichenoid dermatitis associated with imatinib mesylate. Dermatol Online J 2007; 13: 29.
9. Deguchi N, Kawamura T, Shimizu A, Kitamura R, Yanagi M, Shibagski N, et al. Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukemia. Br J Dermatol 2006; 143: 1216-1217.
10. Guilhot F. Indications for imatinib mesylate therapy and clinical management. The Oncologist 2004; 9: 271-281.
11. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol 2008; 58: 545-570.
12. Daele PLA, Dik WA, Thio HB, Hal PTW, Laar JAM, Hooijkaas H, et al. Is imatinib mesylate a promising drug in systemic sclerosis? Arth Rheum 2008; 58: 2549-2552.
13. Sabnami I, Zucker MJ, Rosenstein ED, Baran DA, Arroyo LH, Tsang P, et al. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatol 2008; 48: 49-52
14. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arth Rheum 2008; 58: 2543-2558.
15. Feininger MW, O'Brien SG, Ford M. Practical management of patients with chronic myelid leukemia receiving imatinib. J Clin Oncol 2003; 21: 1637-1647.
16. Raanani P, Goldman JM, Ben-Bassat I. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571. J Clin Oncol 2002; 20: 869-870.
17. Leong KW, Lee TC, Goh AS. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2004; 100: 2486-2487.